|
"楊志新"的相关文件
显示项目 46-70 / 209 (共9页)
<< < 1 2 3 4 5 6 7 8 9 > >>
每页显示[10|25|50]项目
| 國立臺灣大學 |
2015 |
A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.
|
Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil; 林家齊; 楊志新 |
| 國立臺灣大學 |
2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.
|
Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 余忠仁; 何肇基; 施金元; 李日翔 |
| 國立臺灣大學 |
2015 |
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
|
Lee, Chee Khoon; Wu, Yi-Long; Ding, Pei Ni; Lord, Sarah J.; Inoue, Akira; Zhou, Caicun; Mitsudomi, Tetsuya; Rosell, Rafael; Pavlakis, Nick; Links, Matthew; Gebski, Val; Gralla, Richard J.; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang, James C-H; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long; 楊志新; 余忠仁 |
| 國立臺灣大學 |
2015 |
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
|
Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
|
Kim, Dong-Wan; Yang, James Chih-Hsin; Chen, Kan; Cheng, Ziqiang; Yin, Lucy; Martin, Paul David; Yang, Zhenfan; Jiang, Haiyi; Ahn, Myung-Ju; 楊志新 |
| 國立臺灣大學 |
2015 |
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
|
Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A.; 楊志新 |
| 國立臺灣大學 |
2015 |
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu-Yun; Hsu, Chiun; Cheng, Wen-Fan; Cheng, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 郭漢岳; 郭弘揚; 鄭文芳; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 許駿 |
| 國立臺灣大學 |
2015 |
The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases
|
Chiang, Yun; Yang, James Chih-Hsin; Hsu, Feng-Ming; Chen, Yu-Hsuan; Shih, Jin-Yuan; Lin, Zhong-Zhe; Lan, Keng-Hsueh; Cheng, Ann-Lii; Kuo, Sung-Hsin; 楊志新; 郭頌鑫; 鄭安理; 陳育瑄; 藍耿學; 施金元; 許峰銘 |
| 國立臺灣大學 |
2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
Liao, Bin-Chi; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志 |
| 國立臺灣大學 |
2015 |
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
|
Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
|
Liao, Bin-Chi; Lin, Chia-Chi; Shih, Jin-Yuan; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 施金元 |
| 國立臺灣大學 |
2015 |
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
|
Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M.; 楊志新 |
| 國立臺灣大學 |
2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K.; 楊志新 |
| 國立臺灣大學 |
2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao, Bin-Chi; Lee, Jih-Hsiang; Lin, Chia-Chi; Chen, Ya-Fang; Chang, Chin-Hao; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 陳雅芳; 余忠仁; 何肇基; 施金元; 李日翔; 張晉豪 |
| 國立臺灣大學 |
2015 |
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene
|
Wu, Hsu; Shih, Jin-Yuan; Yang, James Chih-Hsin; 楊志新; 施金元 |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
| 國立臺灣大學 |
2015 |
Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
|
Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新 |
| 國立臺灣大學 |
2015 |
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
|
Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm; 楊志新 |
| 國立臺灣大學 |
2015 |
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
|
Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A.; 楊志新 |
| 國立臺灣大學 |
2015 |
Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation
|
Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin; 楊志新; 施金元; 陳珍信 |
| 國立臺灣大學 |
2015 |
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新 |
| 國立臺灣大學 |
2015 |
TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC
|
Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony; 楊志新 |
| 國立臺灣大學 |
2015 |
Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with Met plus EGFRm plus NSCLC
|
Kim, Dong-Wan; Soo, Ross; Yang, James Chih-Hsin; Park, Keunchil; Stammberger, Uz; Xiong, Huiiling; Ihling, Christian; Wu, Yi-Long; 楊志新 |
| 國立臺灣大學 |
2014 |
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations
|
Chen, Yen-Fu; Hsieh, Min-Shu; Wu, Shang-Gin; Chang, Yih-Leong; Shih, Jin-Yuan; Liu, Yi-Nan; Tsai, Meng-Feng; Tsai, Tzu-Hsiu; Yu, Chong-Jen; Yang, James Chih-Hsin; Yang, Pan-Chyr; 楊志新; 張逸良; 楊泮池; 余忠仁; 謝明書; 吳尚俊; 陳瑛芳; 蔡子修; 施金元 |
显示项目 46-70 / 209 (共9页)
<< < 1 2 3 4 5 6 7 8 9 > >>
每页显示[10|25|50]项目
|
